Published in J Thromb Haemost on April 16, 2007
Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation (2013) 1.76
A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab (2010) 1.09
PAI-1 antagonists: the promise and the peril. Trans Am Clin Climatol Assoc (2011) 0.93
The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood (2011) 0.90
High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci (2008) 0.87
Therapeutic potential and anti-amyloidosis mechanisms of tert-butylhydroquinone for Alzheimer's disease. J Alzheimers Dis (2011) 0.83
Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension? Circulation (2013) 0.81
The vitronectin-binding domain of plasminogen activator inhibitor-1 plays an important functional role in lipopolysaccharide-induced lethality in mice. J Thromb Haemost (2012) 0.78
PAI-1 is a critical regulator of FGF23 homeostasis. Sci Adv (2017) 0.75
Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. JAMA (1994) 3.86
Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol (1999) 3.35
Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science (1995) 3.10
Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med (1988) 2.98
Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci U S A (1997) 2.34
Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry (1992) 2.30
Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J Clin Invest (2000) 2.21
Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol (2000) 2.12
Angiotensin-converting enzyme inhibitors. Circulation (1998) 2.10
Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet (1993) 2.09
Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol (1996) 1.94
Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore) (1988) 1.91
Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol (1998) 1.88
Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest (2001) 1.83
Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int (2000) 1.81
Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet (1994) 1.79
Alopecia areata in aging C3H/HeJ mice. J Invest Dermatol (1994) 1.78
Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo. J Clin Invest (1999) 1.76
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol (2000) 1.74
The visualization of human erythrocyte membrane proteins and glycoproteins in SDS polyacrylamide gels employing a single staining procedure. Anal Biochem (1976) 1.72
Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trélat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med (1987) 1.66
Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif (1991) 1.60
Inflammatory bowel disease in glycogen storage disease type Ib. J Pediatr (1986) 1.57
Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol (1986) 1.56
Preoperative thyroid scanning in presumed thyroglossal duct cysts. Arch Otolaryngol Head Neck Surg (1992) 1.55
Plaque morphology and pathologic changes in arteries from patients dying after coronary balloon angioplasty. J Am Coll Cardiol (1990) 1.54
Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol (1992) 1.48
Mercury exposure and cutaneous disease. J Am Acad Dermatol (2000) 1.47
Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol (1998) 1.46
The dynamic link between the integrity of the immune system and zinc status. J Nutr (2000) 1.45
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int (2000) 1.44
Estimation of left ventricular mass and infarct size from nitrogen-13-ammonia PET images based on pathological examination of explanted human hearts. J Nucl Med (1993) 1.44
Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation (2001) 1.44
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol (2000) 1.44
The North American experience with photopheresis. Ther Apher (1999) 1.42
Role of epidermal growth factor in carcinogenesis. Cancer Res (1986) 1.41
Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation (1996) 1.40
An evaluation of the accuracy of residency applicants' curricula vitae: are the claims of publications erroneous? J Am Acad Dermatol (1996) 1.40
Transgenic mice as a model to study the role of TGF-beta-related molecules in hair follicles. Genes Dev (1993) 1.40
Maintaining long-term central venous access by repetitive hepatic vein cannulation. J Pediatr Surg (1994) 1.39
Rapid quantitation of apoptosis in pure and heterogeneous cell populations using flow cytometry. J Immunol Methods (1994) 1.36
Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int (1997) 1.35
Targeted overexpression of transforming growth factor alpha in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous, squamous papillomas. Cell Growth Differ (1993) 1.33
Indications for pediatric intestinal transplantation: a position paper of the American Society of Transplantation. Pediatr Transplant (2001) 1.32
Primary follicular dystrophy with scarring dermatitis in C57BL/6 mouse substrains resembles central centrifugal cicatricial alopecia in humans. Vet Pathol (2010) 1.32
Characterization by electrophoresis of epidermal growth factor stimulated phosphorylation using A-431 membranes. Biochemistry (1980) 1.31
Repair of pectus excavatum deformities: 30 years of experience with 375 patients. Ann Surg (2000) 1.30
Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation (2000) 1.28
What is the 'true' function of skin? Exp Dermatol (2002) 1.26
Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation (1993) 1.26
Management of alopecia areata. BMJ (2010) 1.25
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet (1988) 1.24
Cardiac fungal infections: review of autopsy findings in 60 patients. Hum Pathol (1984) 1.23
Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol (1990) 1.23
Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem (1998) 1.22
Effects of left ventricular shape and captopril therapy on exercise capacity after anterior wall acute myocardial infarction. Am J Cardiol (1989) 1.21
Quantification of apoptotic events in pure and heterogeneous populations of cells using the flow cytometer. Methods Cell Biol (1995) 1.21
Squamous cell carcinoma arising in dissecting perifolliculitis of the scalp. A case report and review of secondary squamous cell carcinomas. J Am Acad Dermatol (1981) 1.21
Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res (2001) 1.21
Identification of the substance binding pemphigus antibody and concanavalin A in the skin. J Invest Dermatol (1974) 1.20
Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1. Nat Struct Biol (1995) 1.20
Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int (2006) 1.19
Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab (1999) 1.19
Chronic elevation of plasma corticosterone causes reductions in the number of cycling cells of the B lineage in murine bone marrow and induces apoptosis. Immunology (1993) 1.17
The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem (1998) 1.17
Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol (1996) 1.16
Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer (2000) 1.15
Current aspects of biology, risk assessment, and treatment of neuroblastoma. Semin Surg Oncol (1999) 1.15
Methodology standards associated with quality reporting in clinical studies in pediatric surgery journals. J Pediatr Surg (2001) 1.15
What causes alopecia areata? Exp Dermatol (2013) 1.14
Comparison of alopecia areata in human and nonhuman mammalian species. Pathobiology (1998) 1.14
Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol (1984) 1.14
Necrotic arachnidism. J Am Acad Dermatol (2001) 1.13
Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension (1998) 1.12
Mouse mutations as animal models and biomedical tools for dermatological research. J Invest Dermatol (1996) 1.12
Nineteen documented cases of Loxosceles reclusa envenomation. J Am Acad Dermatol (2001) 1.12
Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab (2000) 1.11
A direct role for the macrophage low density lipoprotein receptor in atherosclerotic lesion formation. J Biol Chem (1999) 1.10
Skeletal muscle composition in dietary obesity-susceptible and dietary obesity-resistant rats. Am J Physiol (1992) 1.09
A comparison of combinatorial partitioning and linear regression for the detection of epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms on plasma PAI-1 levels. Clin Genet (2002) 1.08
The psychogeriatric nurse in home health care: use of research to develop the role. Clin Nurse Spec (1996) 1.07
Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension (1999) 1.07
Calcium effects on human erythrocyte membrane proteins. Biochim Biophys Acta (1977) 1.07
Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol (1993) 1.07
Acute pulmonary embolism treated with tissue plasminogen activator. Lancet (1986) 1.06
Quantitative determination of EGF-R during epidermal wound healing. J Invest Dermatol (1992) 1.06
Functional and structural characteristics of EGF and its receptor and their relationship to transforming proteins. J Cell Biochem (1986) 1.06
Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol (1992) 1.06
Prothrombotic effects of angiotensin. Adv Intern Med (2000) 1.05
Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther (2006) 1.04
Acquired coronary arterial aneurysms: an autopsy study of 52 patients. Hum Pathol (1986) 1.04
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol (2000) 1.04
Retroviral gene therapy in ApoE-deficient mice: ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation (1999) 1.04
Erythroderma: review of 82 cases. South Med J (1986) 1.03
Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells. Circ Res (1996) 1.02
Percutaneous drainage of abdominal fluid collections in children. AJR Am J Roentgenol (1984) 1.02
Glucocorticoids and irradiation-induced apoptosis in normal murine bone marrow B-lineage lymphocytes as determined by flow cytometry. Immunology (1993) 1.02
Spontaneous alopecia areata-like hair loss in one congenic and seven inbred laboratory mouse strains. J Investig Dermatol Symp Proc (1999) 1.02
Dapsone treatment of a brown recluse bite. JAMA (1983) 1.02